LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

9.65 6.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.54

Max

9.76

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.1M -17M
Pelno marža	-2,321.599
Darbuotojai	55
EBITDA	4.7M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+44.63% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	146M 520M
Ankstesnė atidarymo kaina	2.78
Ankstesnė uždarymo kaina	9.65

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-19 17:29; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025-12-19 16:47; UTC

Pagrindinės rinkos jėgos

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025-12-19 16:10; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025-12-20 19:00; UTC

Uždarbis

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

2025-12-19 22:33; UTC

Uždarbis

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025-12-19 22:19; UTC

Uždarbis

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-19 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 21:44; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 21:38; UTC

Uždarbis

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025-12-19 21:00; UTC

Rinkos pokalbiai

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025-12-19 20:23; UTC

Rinkos pokalbiai

Oil Futures End Down Week on Up Note -- Market Talk

2025-12-19 20:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025-12-19 18:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025-12-19 18:00; UTC

Rinkos pokalbiai

Uždarbis

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025-12-19 17:41; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 17:24; UTC

Rinkos pokalbiai

Uždarbis

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-19 16:29; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025-12-19 16:20; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025-12-19 16:19; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025-12-19 16:18; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025-12-19 16:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-19 16:16; UTC

Rinkos pokalbiai

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025-12-19 16:05; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 16:04; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 15:37; UTC

Rinkos pokalbiai

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

2025-12-19 15:21; UTC

Rinkos pokalbiai

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

2025-12-19 15:09; UTC

Rinkos pokalbiai

Gold Flat But Set for Weekly Gains -- Market Talk

2025-12-19 15:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

44.63% į viršų

12 mėnesių prognozė

Vidutinis 14 USD 44.63%

Aukščiausias 15 USD

Žemiausias 13 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.